Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma

References

• Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008;142:149–165.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009:542–451.
   PubMedGoogle Scholar
• Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009;114:1469–1476.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Hiddemann W. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Curr Opin Oncol 2008;20:487–494.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Saliba RM, . Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407–4412.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, . Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Hoy SM, McKeage K. Temsirolimus: in relapsed and/or refractory mantle cell lymphoma. Drugs 2010;70:1819–1829.
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, . Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002;1603:31–46.
   PubMed Web of Science ®Google Scholar
• Richardson DR, Kalinowski DS, Lau S, . Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 2009;1790:702–717.
   PubMed Web of Science ®Google Scholar
• Prutki M, Poljak-Blazi M, Jakopovic M, . Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 2006;238:188–196.
   PubMed Web of Science ®Google Scholar
• Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system:relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990;416:491–496.
   PubMedGoogle Scholar
• Habashy HO, Powe DG, Staka CM, . Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 2010;119: 283–293.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Loo M, Bury T, . Soluble and cell-associated transferrin receptor in lung cancer. Br J Cancer 1997;75:1802–1806.
   PubMed Web of Science ®Google Scholar
• Lepelletier Y, Camara-Clayette V, Jin H, . Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 2007;67:1145–1154.
   PubMed Web of Science ®Google Scholar
• Ek S, Bjorck E, Porwit-MacDonald A, . Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica 2004;89:686–695.
   PubMed Web of Science ®Google Scholar
• Noulsri E, Richardson DR, Lerdwana S, . Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 2009;84:170–176.
   PubMed Web of Science ®Google Scholar
• Simonart T, Boelaert JR, Mosselmans R, . Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol 2002;85:95–102.
   PubMed Web of Science ®Google Scholar
• Okada T, Sawada T, Kubota K. Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells. Cancer Lett 2007;248:24–31.
   PubMed Web of Science ®Google Scholar
• Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol 2006;100:116–127.
   Google Scholar
• Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007;6:1982–1994.
   PubMed Web of Science ®Google Scholar
• Cappellini MD. Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007;3:291–299.
   PubMedGoogle Scholar
• Nick H, Acklin P, Lattmann R, . Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065–1076.
   PubMed Web of Science ®Google Scholar
• Zelig U, Kapelushnik J, Moreh R, . Diagnosis of cell death by means of infrared spectroscopy. Biophys J 2009;97:2107–2114.
   PubMed Web of Science ®Google Scholar
• Hallak M, Win T, Shpilberg O, . The anti-leukaemic activity of novel synthetic naphthoquinones against acute myeloid leukaemia: induction of cell death via the triggering of multiple signalling pathways. Br J Haematol 2009;147:459–470.
   PubMed Web of Science ®Google Scholar
• Enari M, Talanian RV, Wong WW, . Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723–726.
   PubMed Web of Science ®Google Scholar
• Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629–635.
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, . Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia:a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597–1602.
   PubMed Web of Science ®Google Scholar
• Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547–583.
   PubMed Web of Science ®Google Scholar
• Cappellini MD. Long-term efficacy and safety of deferasirox. Blood Rev 2008;22(Suppl. 2):S35–S41.
   Web of Science ®Google Scholar
• Lalande M. A reversible arrest point in the late G1 phase of the mammalian cell cycle. Exp Cell Res 1990;186:332–339.
   PubMed Web of Science ®Google Scholar
• Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res 1992;52:4591–4599.
   PubMed Web of Science ®Google Scholar
• Chantrel-Groussard K, Gaboriau F, Pasdeloup N, . The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur J Pharmacol 2006;541:129–137.
   PubMed Web of Science ®Google Scholar
• Hallak M, Vazana L, Shpilberg O, . A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation. Apoptosis 2008;13:147–155.
   PubMed Web of Science ®Google Scholar
• Nurtjahja-Tjendraputra E, Fu D, Phang JM, . Iron chelation regulates cyclin D1 expression via the proteasome:a link to iron deficiency-mediated growth suppression. Blood 2007;109:4045–4054.
   PubMed Web of Science ®Google Scholar
• Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999;94:781–792.
   PubMed Web of Science ®Google Scholar
• Klier M, Anastasov N, Hermann A, . Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097–2105.
   PubMed Web of Science ®Google Scholar
• Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344–352.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Kobayashi C, Hamamura R, . The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009;100:970–977.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Messa E, Carturan S, Maffe C, . Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95:1308–1316.
   PubMed Web of Science ®Google Scholar